Objective: Much has been written on the metabolic syndrome and related recent criteria. However, it remains unclear whether such criteria help clinical practice. This review will evaluate the usefulness of metabolic syndrome criteria to enhance risk prediction for either cardiovascular disease or diabetes. Design: This is a narrative review that is based on the author's experience from relevant publications from his group and from other related research. Results: Although the presence of metabolic syndrome, however defined, is clearly associated with higher risk for vascular disease, the criteria do not enhance coronary heart disease (CHD) prediction from simpler Framingham-based risk scores. The dichotomous nature of metabolic syndrome criteriaFeither you have it or you do notFcombined with the lack of age, low-density lipoprotein cholesterol and smoking account for their inferior predictive value. Metabolic syndrome criteria are, in fact, more strongly associated with incident diabetes, an observation demonstrated in the West of Scotland Coronary Prevention Study (WOSCOPS). This is because three of the five parameters within metabolic syndrome criteria (waist, glucose and triglyceride) are more closely linked to risk for diabetes than risk for CHD. However, screening for prevalent or high risk of incident diabetes is a complex and debated issue and is by no means guaranteed to be widely adopted. Conclusions: Metabolic syndrome criteria do not offer benefits beyond established methods of vascular risk assessment. Thus, the focus in clinical practice should remain on established risk factors (for example, smoking, lipids, blood pressure) both to determine CHD risk, through established charts, and to reduce it.
Introduction
Previous papers in this series have described the background to metabolic syndrome and also illustrated relevant criteria for its identification. Such aspects are therefore not covered herein. Rather this paper will critically appraise whether metabolic syndrome criteria are of clinical use, or if not, why not. It will also make suggestions as to alternative ways forward.
Association of metabolic syndrome with incident vascular event and type 2 diabetes
It was entirely predictable that metabolic syndrome criteria, which include established vascular risk factors such as hypertension and low high-density lipoprotein cholesterol, will be associated with higher risk for incident vascular events. This fact is now well documented in a number of studies inclusive of the West of Scotland Coronary Prevention Study (WOSCOPS). 1 In the latter study, a modified version of the metabolic syndrome was associated with a 70% (95% CI 39-107%) higher risk for incident coronary heart disease (CHD) events in univariate analyses, falling to 30% higher risk in multivariate analyses. The vascular risk also increased in a stepwise manner in men as additional criteria of the syndrome were met ( Figure 1 ). However, in addition to tracking CHD events, WOSCOPS also measured fasting glucose at each 6-monthly visit. Hence, WOSCOPS data were able to associate metabolic syndrome with incident type 2 diabetes, with risk increased by 270% (95% CI 160-408%). Thus, this study was the first to signal a closer association of metabolic syndrome (by NCEP criteria) to incident diabetes risk than to vascular events. This is an important observation as there is arguably more interest in predicting a hard clinical event (acute coronary syndrome) than in simply identifying those at risk for incident diabetes (that is, elevated glucose concentrations above a certain threshold).
Why is metabolic syndrome more closely aligned to diabetes risk?
It is not widely appreciated that an elevated body mass index or waist is around 10 times more strongly linked to diabetes than to incident CHD events. Similarly, elevated fasting glucose concentrations in those without diabetes are not predictive of cardiovascular disease (CVD), but they are of incident diabetes. In WOSCOPS, men with a fasting glucose 45.0 mmol l À1 but o7 mmol l À1 had a hazard ratio of Whether all such patients identified at high risk by questionnaire or history require an OGTT remains debatable. Certainly, an OGTT is the best means to pick up those with prevalent type 2 diabetes, but it is labour intensive and costly. Rather than an OGTT in all, perhaps a two-step process could be employed, using a glycated haemoglobin (±fasting glucose) as the first step to screen out those who are either very unlikely to have diabetes (low HBA1c for example, o5.8%) or those with diabetes (fasting glucose 47 mmol l
À1
) and then to perform an OGTT in those in the grey area between. This suggestion is speculative but requires more research, although others have shown a good sensitivity and specificity of glycated haemoglobin for a similar purpose. 4 The present recommendations 5 by the ESC/EASD on the need for an OGTT in all CHD subjects not known to have diabetes are simply unrealistic. What we really need to know is who has unknown diabetes, and thus an initial clinical measurement of glycated haemoglobin may be of value as a first step, with an OGTT restricted to a minority who are shown to be at high risk on the basis of their glycated haemoglobin measurement. This approach requires further research, but there is insufficient data to reject it as a more feasible two-step alternative to OGTTs in all. It should also be noted that knowing whether an individual with prevalent vascular disease has impaired glucose tolerance by OGTT is unlikely to substantially alter their management. Such subjects should already be on cardioprotective agents and also have been counselled about lifestyle measures. Furthermore, recent evidence suggests that perhaps only those CHD subjects with new or known diabetes, but not those with impaired glucose tolerance, have increased risk of subsequent vascular events, at least in the short term. can be made on non-fasting blood in the majority of individuals, as cholesterol and high-density lipoprotien cholesterol are not measurably altered in the post-prandial state and triglyceride is not considered. Thus, not only are Framingham-based risk charts more predictive than metabolic syndrome criteria, but they are also able to be determined on non-fasting samples, an advantage in clinical practice.
Why the metabolic syndrome criteria are inferior to Framingham-based risk scores
This is perhaps partly illustrated by a case example (Table 1) . Let us take two patients; one (Mr A) has a metabolic syndrome by any of the commonly used definitions but the other (Mr B) does not. However, Mr B is clearly at much higher cardiovascular risk because he is older and he smokes and has a much higher level of low-density lipoprotein cholesterol. None of these three factors, however, is included in the metabolic syndrome cluster. In addition, the dichotomous nature of all metabolic syndrome criteriaFeither you have metabolic syndrome or you do notFis a major limitation. It is clear that vascular risk does not simply and wholly 'manifest' beyond arbitrary cutoffs; rather, risk factors mostly show a linear association with CVD. Finally, three of the components of the metabolic syndrome have been insufficiently tested as predictors of vascular events in prospective studies; glucose, triglyceride and waist circumference require further data to test their predictive ability for vascular events and, as noted above and previously, 13 all three are more closely aligned to prediction of type 2 diabetes. A summary of the limitations of the current criteria is given in Table 2 .
A better way ahead to improving CVD risk prediction/screening?
Rather than invent new criteria that try to link to both CHD and diabetes (end points that are not interchangeable), it would be better to concentrate on new potential risk factors for vascular events only and to do so one at a time. This should be done by comparing the predictive ability (using appropriate statistical tests and continuous rather than dichotomized measures) of any new risk factor in conjunction with established CVD risk factors or algorithms. One possible candidate is apolipoprotein B, which may be superior to low-density lipoprotein cholesterol in CVD risk prediction. 14 Interestingly, we noted that apolipoprotein B correlates with insulin resistance-related features much better than low-density lipoprotein cholesterol (Figure 2) , and of course apolipoprotein B is a good measure of atherogenic low-density lipoprotein particle number. 15 In addition, there is emerging interest in brain natriuretic peptide for risk factor prediction, but once again there is a need for larger studies. 16 Alternatively, other newer risk Are there any benefits from the recent surge of interest in metabolic syndrome?
In fairness to researchers responsible for developing recent metabolic syndrome criteria, one of their main goal was to promote greater research and discussion on relevant issues, and this has certainly been achieved. In addition, some modest 'indirect' benefits may have arisen. Perhaps most importantly, the advent of the NCEP criteria and associated surge of publications in cardiovascular journals has most likely increased cardiologists' and vascular physicians' interest and understanding of the links between different risk pathways, inclusive of obesity and insulin resistance. Accordingly, cardiologists perhaps now place more emphasis on at least documenting obesity and glycaemic dysregulation in their patients. All physicians may also consider emphasizing lifestyle changes, in particular physical activity, more often in the management of their patients. Finally, the surge of interest in metabolic syndrome and the greater emphasis and research recently on the use of waist circumference has been useful. Obesity levels continue to rise worldwide and any research that enhances relevant information, improves public understanding of the issues, and stimulates preventative measures must be welcomed. Of course, it could easily be argued that rather than an emphasis on metabolic syndrome, obesity management and its prevention should be the real focus of attention. 17 
Conclusion
Despite considerable recent interest and many relevant publications on the topic of the metabolic syndrome, there is currently no clear evidence at present to justify using any of the current metabolic syndrome definitions in clinical practice for purposes of vascular risk estimation or diabetes screening. It is also clear that vascular events and new-onset diabetes are not interchangeable end points that should be combined and that risk factors for each end point differ sufficiently as to make unified criteria impossible and ineffectual. An alternative approach would be to concentrate on new potential risk factors for vascular events only and to do so one at a time. In the meantime, the current focus in clinical practice should remain on established risk factors (for example, smoking, lipids, blood pressure) both to determine vascular risk, through established risk charts, and to reduce it. 'captures' more of the risk associated with insulin resistance and associated factors than does low-density lipoprotein cholesterol (LDL-C). Adapted from Williams et al.
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